Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Should Rx Patient Leaflets Be Labeled Like Dietary Supplements?

This article was originally published in The Pink Sheet Daily

Executive Summary

If patient medication information documents noted when they were not FDA approved, it might relieve some pre-marketing review burden on the agency, but officials worry consumers will not trust the information.
Advertisement

Related Content

Assurance Vs. Flexibility: Unit-Of-Use Packaging Offers Trade-Offs For Patient Leaflets
Assurance Vs. Flexibility: Unit-Of-Use Packaging Offers Trade-Offs For Patient Leaflets
FDA Must Maintain Oversight Role In PMI Development, Groups Urge
FDA Must Maintain Oversight Role In PMI Development, Groups Urge

Topics

Advertisement
UsernamePublicRestriction

Register

PS071249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel